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The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1 and the associated coronavirus disease 2019 (COVID-19)2,3 continue to spread throughout the world, 
causing >120 million infections and >2.6 million deaths (16 
March 2021, Johns Hopkins COVID-19 Dashboard). Genomic 
surveillance has played a key role in the response to the pandemic; 
sequenced data from SARS-CoV-2 provides information on the 
transmission patterns and evolution of the virus as it enters new 
regions and spreads. As COVID-19 vaccines become available and 
are implemented, monitoring SARS-CoV-2 genetic changes, espe-
cially changes at the epitopes with implications for immune escape 
is crucial. A detailed classification system has been defined to help 
monitor SARS-CoV-2 as it evolves4, with virus sequences classified 
into two main phylogenetic lineages (Pango lineages) A and B, rep-
resenting the earliest divergence of SARS-CoV-2 in the pandemic 
and then into sublineages within these. Several variants of concern 
(VOCs) have emerged showing increased transmission patterns and 
reduced susceptibility to vaccine and/or therapeutic antibody treat-
ments. These VOCs include lineage B.1.1.7, first identified in the 
UK5, B.1.351 in South Africa6 and lineage P.1 (B.1.1.28.1) in Brazil7.
Status of the SARS-CoV-2 epidemic in Uganda
SARS-CoV-2 infection was first detected in Uganda in March 2020, 
initially among international travellers until passenger flights were 
stopped in late March 2020. A second route of virus entry with 
truck drivers from adjacent countries then became apparent8. Since 
August 2020, community transmission dominated the Uganda case 
numbers. By March 2021, total cases in Uganda were 40,535, with 
334 deaths attributed to the virus. We have continued our efforts 
to generate SARS-CoV-2 genomic sequence data to monitor virus 
movement and genetic changes and we report in this article on a 
new sublineage A (A.23.1) that has emerged and is dominating the 
local epidemic. The A.23.1 variant encodes multiple changes in the 
spike protein as well as in nsp6, ORF8 and ORF9, some predicted 
to be functionally similar to those observed in VOCs in lineage B.
Changes in prevalence of lineage A viruses
The genomes generated in this study were classified into Pango 
lineages4 using the pangolin module pangoLEARN (https://github.
com/cov-lineages/pangolin) and into Nextstrain clades using 
Nextclade9 (https://clades.nextstrain.org/). The distribution of 
virus lineages circulating in Uganda changed dramatically over the 
course of the year. A clear feature of the earlier COVID-19 epidemic 
in the country was the diversity of viruses found throughout the 
country attributed to frequent flights into Uganda from Europe, 
UK, US and Asia; this is reflected in the nine lineages seen from 
March to May 2020 with a mixture of both lineage A and B viruses 
(Fig. 1a). After passenger flights were limited in March 2020, the 
virus entered by land travel via truck drivers. Uganda is landlocked 
country, characterized by its important geographical position, that 
is, the crossing of two main routes of the Trans-Africa Highway in 
East Africa. The essential nature of produce and goods transport 
allowed virus movement from/to Kenya, South Sudan, Democratic 
Republic of the Congo, Rwanda and Tanzania. In the period from 
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June to August 2020, the lineage B.1 and B.1.393 strains were abun-
dant, similar to patterns observed in Kenya10 (Fig. 1b) although lin-
eage A viruses did not decline as seen in US and Europe. Lineage 
A.23 strains were first observed in two prison outbreaks in Amuru 
and Kitgum, Uganda in August 2020; by September–November, 
A.23 was the major lineage circulating throughout the country 
(Fig. 1c). The A.23 virus continued to evolve into the A.23.1 lin-
eage, first observed in late October 2020. Given the diversity of virus 
lineages found in the country from March until November 2020, it 
was unexpected that by late December 2020 to January 2021, lineage 
A.23.1 viruses represented 90% (102 of 113 genomes) of all viruses 
observed in Uganda (Fig. 1d). In all time periods, the SARS-CoV-
2-positive sample were obtained from multiple clinical and sur-
veillance locations throughout Uganda (Extended Data Fig. 5b), 
indicating that the differences are unlikely to be due to sampling 
different subpopulations in the country at different times.
Virus sequence diversity
All newly and previously generated Uganda genomes that were 
complete and high-coverage (n = 322) were used to construct a 
maximum-likelihood phylogenetic tree (Fig. 2).
A number of A and B variant lineages were observed briefly at 
low frequencies and may have undergone extinction, similar to pat-
terns observed in the UK11,12. Although based on limited sampling, 
genomes identified from a truck driver are often observed basal to 
community clusters (Fig. 2), suggesting the importance of this route 
in the introduction and spread of the virus into Uganda. Most of 
the genomes from truck drivers sampled at ports of entry (POEs) 
bordering Kenya belonged to lineage B.1 and B.1.393, which is 
consistent with the pattern reported in Kenya10. However, genomes 
identified from truck drivers from Tanzania and from the Elegu 
POE bordering South Sudan, albeit small numbers, belonged to 
both the A and B.1 lineages. Continued monitoring of truck drivers 
coming in and out of Uganda provides a useful description of the 
inland circulation of strains in this part of world, where genomic 
surveillance is not as detailed as in other parts of the world.
Emergence of A.23 and A.23.1
Outbreaks of SARS-CoV-2 infections were reported in the Amuru 
and Kitgum prisons in August 2020 (ref. 13,14). The SARS-CoV-2 
genome sequences from individuals in the prisons were exclu-
sively belonging to lineage A (Fig. 2) with three amino acid changes 
encoded in the spike protein (F157L, V367F and Q613H; Fig. 3) that 
now define lineage A.23. By October 2020, lineage A.23 viruses were 
also found outside of the prisons in a community sample from Lira 
(a town 140 km from Amuru), in two samples from the Kitgum hos-
pital, in several community samples from Kampala, Jinja, Mulago, 
Tororo and Soroti as well as in 2 truck drivers collected at the POE 
bordering Kenya. By November 2020, the A.23 viruses had spread 
further to northern Uganda in Gulu and Adjumani, as observed 
in this study. Lineage A.23 viruses were not seen in Uganda (or 
anywhere in the world) before August 2020 (Fig. 3c), yet the A.23 
viruses were attributed to 32% of the viruses in Uganda (Fig. 1) from 
June to August 2020 and 50% of the observed viruses in September–
November 2020. In late October, the A.23.1, a variant evolving 
from A.23, with additional change in the spike protein (P681R) was 
observed (Fig. 3b,c); by December 2020 to January 2021, 90% of 
identified genomes (102 out of 113) belonged to the A.23.1 lineage 
(Figs. 1 and 2). The mutations in A.23.1 were consistent with evolu-
tion from an original A.23 virus observed in the Amuru/Kitgum 
cluster (Fig. 2 and Extended Data Fig. 1) as well as changes in nsp6 
and ORF9 (Extended Data Figs. 2 and 4).
Important changes observed in the spike protein
The spike protein is crucial for virus entry into host cells, for tro-
pism and is a critical component of COVID-19 vaccine develop-
ment and monitoring. The changes in spike protein observed 
in Uganda and the global A.23 and A.23.1 viruses are shown in 
Fig. 3b. Many amino acid changes were single events with no apparent 
transmission observed. However, the initial lineage A.23 genomes 
from Amuru and Kitgum encoded three amino acid changes in the 
exposed S1 domain of the spike protein (F157L, V367F and Q613H; 
Fig. 3b). The V367F change is reported to modestly increase infec-
tivity15 and the Q613H change may have similar consequences as 
the D614G change observed in the B.1 lineage found predominantly 
in Europe and the US; in particular, D614G was reported to increase 
infectivity, spike trimer stability and furin cleavage15–18. These 
changes were not observed in previously reported genomes from 
Uganda8. Of some concern, the mutations E484K and N501Y amino 
acid changes in the receptor-binding domain were observed in the 
A.23 viruses identified in the Adjumani cases on 9–11 November 
2020 (Fig. 3b). These two amino acid changes are shown to substan-
tially compromise vaccine efficacy and antibody treatments.
Of concern, the recent Kampala and global A.23.1 virus sequences 
from December 2020 to January 2021 now encoded 4 or 5 amino 
acid changes in the spike protein (now defining lineage A.23.1) 
plus additional protein changes in nsp3, nsp6, ORF8 and ORF9 
(Figs. 3b and 4). The substitution of proline by arginine at spike 
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Fig. 1 | SARS-CoV-2 lineage diversity in Uganda. All high-coverage complete sequences from Uganda (n = 322) were lineage-typed using the pangolin 
resource (https://github.com/cov-lineages/pangolin). Lineage counts were stratified into four periods: March–May 2020 (a); June–August 2020 (b); 
September–November 2020 (c); and December 2020 to January 2021 (d). The percentage of each lineage within each set was plotted as a treemap using 
squarified treemap41 implemented in squarify (https://github.com/laserson/squarify) with the size of each sector proportional to the number of genomes; 
genome numbers are listed with ‘n = ’.
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position 681 importantly adds a positively charged amino acid 
adjacent to the cleavage site for the host furin protease. An identi-
cal proline to arginine change enhances the fusion activity of the 
SARS-CoV-2 spike protein in in vitro experiments and this has 
been proposed to increase spike protein cleavage by the cellular 
furin protease19; importantly, a similar change (P681H) is encoded 
by the recently emerging VOC B.1.1.7 that is spreading globally 
across 75 countries as of 5 February 2021 (refs. 5,20). There are also 
changes in the spike N-terminal domain, a known target of immune 
selection, observed in samples from the Kampala A.23.1 lineage, 
including P26S and R102I (Fig. 3b). Additionally and importantly, 
an A.23.1 strain identified in Kampala on 11 December 2020 car-
ried the E484K change in the receptor-binding domain, which may 
add further concern of this particular variant as it gains higher 
transmissibility and enhanced resistance to vaccines and thera-
peutics. Outside of the spike protein, a single nucleotide change 
(G27870T) leading to early termination of ORF7b (E39*) was 
observed in the A.23.1 from the community cases in Tororo in late 
December 2020. Although the clinical implication of this change is 
yet to be determined, it is important to document such changes for 
further follow-up.
Lineage A designations
The viruses detected in Amuru and Kitgum met the criteria for a 
SARS-CoV-2 lineage4,21 by clustering together on a global phy-
logenetic tree, sharing epidemiological history and source from 
a single geographical origin and encoding multiple defining 
single-nucleotide polymorphism (SNPs). These features, especially 
the three spike changes F157L, Q613H and V367F, define the A.23 
lineage. Continued circulation and evolution of A.23 in Uganda was 
observed and two additional changes in spike R102I and P681R 
were observed in December 2020 in Kampala, with the later amino 
acid change adding to the list of defining SNPs for the sublineage 
A.23.1 (F157L, V367F, Q613H and P681R). Additional changes in 
non-spike regions also define the A.23 and A.23.1 lineages, includ-
























Fig. 2 | Maximum-likelihood phylogenetic tree comparing all available complete and high-coverage Uganda sequences (n = 322). Strain names are 
coloured according to the case profile: cases from the community, dark red; prison, orange; truck driver, light brown; return traveller, light blue. The case 
clusters from prisons in Kitgum and Amuru are highlighted in colour boxes in light yellow and light green, respectively. Lineages A.23 and A.23.1 are 
indicated. The tree was rooted where lineages A and B were split. Branch length is drawn to the scale of the number of nucleotide substitutions per site, 
indicated in the lower left; only bootstrap values of major nodes are shown.
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Fig. 3 | Spike protein changes in lineage A.23 and A.23.1 relative to the SARS-CoV-2 reference strain (NC_045512) encoded protein. a, The locations 
of important spike protein features are indicated. b, Each line represents the encoded spike protein sequence from a single genome, ordered by date 
of sample collection (bottom earliest, top most recent). Sequences from Amuru in August 2020, Kitgum in September 2020 and Uganda in October, 
November and December 2020/January 2021 are indicated. Coloured markers indicate the positions of amino acid substitutions from the reference strain 
sequence; only substitutions observed in multiple genomes are annotated with the annotation (original amino acid position, new amino acid) and the 
labels were placed as close as possible to the substitution. c, Current global temporal distribution of A.23 and A.23.1. All available SARS-CoV-2 genomes 
annotated as complete and lineage A from GISAID were retrieved on 4 February 2021 and lineage-typed using pangolin and confirmed as A.23 and A.23.1 
by extracting and examining the encoded spike protein. All new Uganda A.23 and A.23.1 reported in this study were also included. Genomes were plotted 
by country and sample collection date.
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N: S202N, Q418H. These lineages can be assigned since pangolin 
v.2.1.10 and pangoLEARN data release 2021-02-01.
Screening SARS-CoV-2 genomic data from GISAID (12 March 
2021), the A.23 and A.23.1 viruses were found in 26 countries 
outside of Uganda (Fig. 3c). A.23 was first observed in Uganda in 
August 2020, subsequently in the US in October and Kenya and 
Rwanda in December (Fig. 3c). The first A.23.1 genomes in Uganda 
were detected in community cases in Mbale on 28 October 2020 
and in Jinja on 29 October 2020 and were soon spreading across 
the country in early November 2020. Outside Uganda, A.23.1 was 
found in England and Cambodia from the end of November and 
in Rwanda from the beginning of December. Of note, international 
flights out of Uganda were restarted on 1 October 2020 with flights 
to Europe, Asia and the US. Phylogenetic analysis supported the 
evolution of A.23 to A.23.1 (Extended Data Fig. 1).
Additional changes in the A.23 and A.23.1 genomes from 
Uganda compared to other VOC genomes
Although a main focus has been on spike protein changes, there 
are changes in other genomic regions of the SARS-CoV-2 virus 
accompanying the adaptation to human infection. We employed 
profile Hidden Markov Models (pHMMs) prepared from 44 
amino acid peptides across the SARS-CoV-2 proteome22 to detect 
and visualize protein changes from the early lineage B reference 
strain NC_045512. Measuring the identity score (bit-score) of 
each pHMM across a query genome provides a measure of protein 
changes in 44 amino acid steps across the viral genome (Fig. 4). This 
method applied to the A.23 and A.23.1 genome sequences revealed 
the changes in spike and changes in the transmembrane protein 
nsp6 and interferon modulators ORF8 and ORF9 (Fig. 4).
We asked if a similar pattern of evolution was appearing in VOCs 
as SARS-CoV-2 adapted to human infection. We gathered the sets 
of genomes described in the initial published descriptions of these 
VOCs (B.1.1.7 (ref. 5), B.1.351 (ref. 23) or P.1 (ref. 7)) and applied the 
same pHMM analysis. Like A.23/A.23.1, the B.1.1.7 lineage encodes 
nsp6, spike, ORF8 and ORF9 changes as well as changes in nsp3 
and RNA-dependent RNA polymerase (RDRP); Fig. 4b). Lineage 
B.1.351 encodes nsp3, nsp6, RDRP, spike and ORF6 changes (Fig. 4c) 
and lineage P.1 encodes nsp3, nsp6, RDRP, nsp13, spike and ORF8 























































































Fig. 4 | Protein changes across lineage variants. All forward open reading frames from the 35 early lineage B SARS-CoV-2 genomes were translated 
and processed into 44 amino acid peptides (with 22 amino acid overlap), clustered at 0.65 identity using uclust39, aligned with MAAFT31 and converted 
into pHMMs using HMMER-3 (ref. 40). The presence of each domain and its bit-score (a measure of the similarity between the query sequence and the 
sequences used for the pHMM40) was sought in each set of SARS-CoV-2 VOC genomes and the 1-mean of the normalized domain bit-scores was plotted 
across the genome (for example, 1—the similarity of the identified query domain to the reference lineage B SARS-CoV-2 domain). Domains are coloured 
by the proteins from which they were derived with the colour code is indicated below the figure. The genome positions of the indicated open reading 
frames are the following: nsp1: 250,805; nsp2: 806,2719; nsp3: 2720,8554; nsp4: 8555,10054; nsp53Cpro: 10055,10972; nsp6TM: 10973,11842; nsp7: 
11843,12091; nsp8Rep: 12092,12685; nsp9RNAbp: 12686,13024; nsp10CysHis: 13025,13441; RDRP: 13442,16236; nsp13hel: 16237,18039; nsp14ExoN: 
18040,19620; nsp15endo: 19621,20658; nsp16OMT: 20659,21552; spike: 21563,25384; ORF3a: 25393,26220; ORF4E: 26245,26472; ORF5M: 
26523,27195; ORF6: 27202,27387; ORF7a: 27394,27759; ORF7b: 27756,27887; ORF8: 27894,28259; ORF9N: 28274,29533; ORF10: 29558,29712. Note 
that ORF7b and ORF10 are too small to be detected by this analysis method. a, The query set are 49 mostly Uganda lineage A.23.1 genomes. b, All B.1.1.7 
full genomes lacking ambiguous nucleotides deposited in GISAID on 26 January 2021 are shown. c, All B.1.351 full genomes lacking ambiguous nucleotides 
present in GISAID on 26 January 2021 are shown. d, All P.1 full genomes lacking ambiguous nucleotides present in GISAID on 26 January 2021 are shown.
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positions of change within the proteins differ in each lineage, there 
are some striking similarities in the common proteins that have 
been altered. Of interest, the nsp6 change present in B.1.1.7, B.1.351 
and P.1 is a 3-amino acid deletion (106, 107 and 108) in a protein 
loop of nsp6 predicted to be on exterior of the autophagy vesicles 
on which the protein accumulates24. The three-amino acid nsp6 
changes of lineage A.23.1 are L98F in the same exterior loop region; 
the M86l and M183I changes are predicted to be in intramembrane 
regions but adjacent to where the protein exits the membrane24 
(Extended Data Fig. 2). The A23.1 ORF8 gene encodes changes in 
the C-terminal domain (Extended Data Fig. 3). A compilation of 
the amino acid changes in A.23.1 and the VOC lineages is found 
in Supplementary Table 1 with proteins that are altered in all four 
lineages marked in red.
Discussion
We report the emergence and spread of a SARS-CoV-2 variant of 
the A lineage (A.23.1) with multiple protein changes throughout 
the viral genome. The pattern of A.23.1 emergence and dominance 
has also been observed in the neighbouring country of Rwanda25. 
A similar phenomenon recently occurred with the B.1.1.7 lineage, 
detected first in the southeast of England5 and now globally, and 
with the B.1.351 lineage in South Africa6 and the P.1 lineage in 
Brazil26 suggesting that local evolution (perhaps to avoid the ini-
tial population immune responses) and spread may be a common 
feature of SARS-CoV-2. Importantly, lineage A.23.1 shares many 
features found in the lineage B VOCs, including alteration of key 
spike protein regions, especially the angiotensin-converting enzyme 
2 binding region, which is exposed and immunogenic, the furin 
cleavage site and the 613/614 change that may increase spike mul-
timer formation. The VOC and A.23.1 strains also encode changes 
in the similar region of the nsp6 protein, which may be important 
for altering cellular autophagy pathways that promote replication. 
Changes or disruption of ORF7, ORF8 and ORF9 are also present in 
the VOC and A.23.1. ORF8 changes or deletion probably indicates 
that this protein is unnecessary for human replication; similar dele-
tions accompanied SARS-CoV-2 adaption to humans27,28.
This study has potential limitations. We report the results of 
full-genome virus sequencing in a resource-limited region dur-
ing a period with severe restraints on reagent procurement, travel 
and laboratory staffing; thus, total numbers were limited to 322 
full genomes. Ideally, all positive cases in the country would be 
sequenced but this was practically not possible. On the other 
hand, the genome to case percentage we reported was 0.79% (322 
genomes/40,490 cases), which is comparable with the case sequenc-
ing rate reported in South Africa (0.2%) and Nigeria (0.37%) for 
comparison. The geographical origin of the genomes (Extended 
Data Fig. 5) shows coverage across the country. Certainly, given the 
small number of genome sequences available from this study and 
from the region, we should caution that the particular evolution-
ary pathway proposed in this study (A.23 emergence in Uganda 
in August, evolution to A.23.1 and then spread to the region and 
globally) is supported by the available sequencing data but limited 
by the less then 100% sequence/case coverage and limited sam-
pling in the region. Alternate pathways are possible if, for example, 
A.23.1 had evolved in Tanzania or another unsampled country and 
then moved into Uganda. Additionally, Uganda or the East Africa 
region does not have the resources to provide the detailed surveil-
lance and diagnostic testing seen in Europe or North America, so 
national or sentinel surveillance may not be as detailed and com-
prehensive as that occurring in the north. Moreover, the MinION 
technology, like all other sequencing technologies currently in use 
(Illumina, Ion Torrent, Sanger Dideoxy), has a sequencing error 
profile. Nonetheless, MinION has been used to generate about 40% 
of over 1 million SARS-CoV-2 sequences now available in GISAID 
and is accepted as a reasonable sequencing technology. To limit any 
potential MinION sequencing errors in our sequences, we have 
reported and analysed only complete, high-coverage sequences 
(>10,000-fold coverage) and have manually checked all single 
nucleotide changes and deletions in the assembled genomes.
Independent of pangolin lineage assignation, it is clear that a 
SARS-CoV-2 lineage emerged (A.23) and evolved into a sublineage 
(A.23.1) that dominated the epidemic in Uganda by January 2021. 
This can be confirmed independently of pangolin use since we 
examined the maximum-likelihood phylogenetic trees (Fig. 2 and 
Extended Data Fig. 1) where the A.23 cluster of genomes is basal 
to the A.23.1 second cluster. Also independent of pangolin use, 
the pattern of amino acid changes observed with the substitutions 
observed in spike proteins from genomes identified as A.23 (F157L, 
V367F, Q613H) is a clear subset of the substitutions observed in 
the genomes designated A.23.1 (F157L, V367F, Q613H, P681R). 
Further support for the pangolin lineage assignation can be seen in 
the global timing of the observations of the two lineages illustrated 
in Fig. 3c, with the lineage A.23 cases observed before the A.23.1 
samples. Certainly, the temporal pattern could have occurred by 
chance in a few places due to sequencing capacity and coverage. 
However, the global temporal pattern, particularly occurring in 
countries with massively extensive sequencing efforts like the UK 
and US, would indicate that the phenomenon is consistent with 
A.23.1 evolving from A.23 and consistent with the lineage classifi-
cation by the pangolin tool.
We suspect that emerging SARS-CoV-2 lineages may be adjust-
ing to infection and replication in humans and it is notable that the 
VOC and A.23.1 lineage share some common features in their evo-
lution. The spike changes are best understood due to the massive 
global effort to define the receptor and develop vaccines against the 
infection. The analysis reported in Fig. 4 reveals common functions 
of SARS-CoV-2 that have been altered in all four variants, espe-
cially nsp6 and ORF8 and ORF9. The functional consequences of 
the additional non-spike changes warrant additional studies and 
the current analysis may focus the efforts of the proteins that are 
commonly changed in the variant lineages. Finally, determining 
the susceptibility of A.23.1 to vaccine immune responses is of great 
importance as vaccines become available in this part of Africa.
Methods
Statistics and reproducibility. No statistical method was used to predetermine 
sample size. The experiments were not randomized and the investigators were not 
blinded to allocation during the experiments and outcome assessment.
Sample collection, whole-genome MinION sequencing and genome assembly. 
SARS-CoV-2 PCR with reverse transcription-positive samples were obtained from 
the Central Public Health Laboratories (Kampala, Uganda). All testing facilities 
across the country contribute to the sample collection at Central Public Health 
Laboratories and the sample catchment area is country-wide, including clinical 
sites, testing sites at border crossings and commercial laboratories testing the entry 
and exit of international travellers. The fraction of genomes per district compared 
to cases per district is shown in Extended Data Fig. 5a and the geographical source 
of the samples across Uganda is shown in Extended Data Fig. 5b. The samples 
reported in this manuscript span the period from the first positive case in Uganda 
(21 March 2020) until 23 January 2021. We attempted to sequence all samples that 
could be shared with us and each sample was only sequenced once (no replication 
was performed).
The nucleic acid extracted from samples was converted to complementary 
DNA and amplified using a SARS-CoV-specific 1,500-base pair amplicon  
spanning the entire genome as described previously29. The resulting DNA 
amplicons were used to prepare sequencing libraries, barcoded individually 
and then pooled to sequence on MinION R.9.4.1 flow cells, according to the 
manufacturer’s standard protocol.
Genome assemblies were performed as described previously8. Briefly, reads 
from FAST5 files were base-called and demultiplexed using Guppy v.3.6 running 
on the UMIC HPC. Adaptor and primer sequences were removed using Porechop 
v.0.2.4 (https://github.com/rrwick/Porechop) and the resulting reads were mapped 
to the reference genome Wuhan-1 (GenBank NC_045512.2) using minimap2-2.17 
(r941)30 and consensus genomes were generated in Geneious Prime 2021.1.1 
(Biomatters). Genome polishing was performed in Medaka v.1.3.4 and SNPs and 
mismatches were checked and resolved by consulting raw reads. To limit any 
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possible MinION sequencing errors in our sequences, we have reported only 
high-coverage sequences and have manually checked all single nucleotide changes 
and deletions in the assembled genomes; non-supported changes have been 
replaced with NS.
Phylogenetic analyses. For the local Uganda virus comparison, all available 
genomes from Uganda (n = 322) were aligned using MAFFT v.7.477 (ref. 31) and 
manually checked in AliView v.1.27 (ref. 32). The 5′ and 3′ untranslated regions 
were trimmed. The maximum-likelihood phylogenetic tree was constructed 
using RAxML-NG v.1.0.2 (ref. 33) under the GTR + I + G4 model as the best-fitted 
substitution model according to the Akaike information criterion determined by 
ModelTest-NG v.0.1.7 (ref. 34) and run for 100 pseudo-replicates. The resulting  
tree was visualized in FigTree v.1.4.4 (ref. 35) and rooted at the point of splitting 
lineages A and B36–38.
For the phylogenetic analyses of the Uganda lineage A.23 and A.23.1 strains 
comparing these to the global A.23/A.23.1 strains, the global SARS-CoV-2 lineage 
A.23 (n = 8) and A.23.1 (n = 38) genomes were retrieved from GISAID on 12 
March 2021. These global A.23/A.23.1 genomes combined with the Ugandan 
A.23/A.23.1 genomes (n = 191) were aligned using MAFFT and manually 
checked in AliView; this was followed by trimming the 5′ and 3′ untranslated 
regions. The global and Ugandan A.23/A.23.1 genomes were used to construct 
a maximum-likelihood tree under the GTR + I + G4 model as the best-fitted 
substitution model according to the Akaike information criterion determined 
by ModelTest-NG34 and run for 100 pseudo-replicates using RAxML-NG. The 
resulting tree was visualized in FigTree and rooted using the A.23 lineage.
The pHMM domain analysis of A.23/A.23.1 and VOC genomes was  
performed as described previously22 with some changes. A database of pHMMs 
was generated from the first 65 lineage B SARS-CoV-2 genome sequences. All 3 
forward open reading frames of each genome were translated computationally 
and then sliced into a 44-amino acid segment overlapping with 22 amino acids. 
All 44 amino acid query peptides were then clustered with the uclust module 
from usearch11.0.667_i86osx32 (ref. 39) and their original identity and coordinates 
determined by BLASTp search against a protein database made from the 
NC_045512 reference strain.
Query sets of genomes were processed to remove any genomes containing 
ambiguous nucleotides, which disrupt the HMM scoring process. The hmmscan 
function from HMMER v.3.3.2 (ref. 40) was used with the early B database. Query 
matches were identified using an E-value cut-off of 0.0001; the bit-score values for 
each hit (a measure of the distance between the query 44-amino acid peptide and 
the lineage B reference) was collected. Bit-scores for each domain were normalized 
by dividing each query score by the maximum score for that domain (x/x_max). In 
all analyses, the original lineage B NC_045512 reference genome was included to 
define the maximum bit-score.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All data, specialized code and instruction relevant to this manuscript are available 
at the GitHub repository https://github.com/mlcotten13/SARSCOV2_NatMicro. In 
addition, the SARS-CoV-2 genomes are available on GISAID (https://www.gisaid.
org/) under accession nos. EPI_ISL_954226–EPI_ISL_954300, EPI_ISL_955136 
and EPI_ISL_1469313–EPI_ISL_1469432. We have also deposited a complete 
alignment of these sequences in the Github repository. Source data are provided 
with this paper.
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Extended Data Fig. 1 | Maximum-likelihood phylogenetic tree comparing Uganda lineage A.23 and A.23.1 strains to global lineage A.23 and A.23.1 
genomes. A maximum-likelihood (ML) phylogenetic tree comparing Ugandan A.23 and A.23.1 (n = 191) with the global A.23 and A.23.1 (N = 336). The 
tree was rooted by the A.23 lineage and strains were coloured according to the countries where they were identified. Branch length was drawn to the scale 
of number of nucleotide substitutions per site and only bootstrap values at the major nodes were shown. The tree was visualised in Figtree3.
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Extended Data Fig. 2 | Changes in A.23/A.23.1 nsp6 protein. The encoded nsp6 protein from all Ugandan A.23 and A.23.1 genomes gather, aligned and 
compared to the nsp6 protein from GenBank NC_045512.2. Panel a: The locations of important nsp6 protein features are indicated based on the analysis 
of nsp6 from Benvenuto et al.4. Intra_N: intravesicular amino-terminal region, Extra_loop_1: extravesicular loop1, Intra_loop_1: intravesicular loop 1, B_del 
106-108: the region of nsp6 deleted in the lineage B VOC genomes, Extra_loop_Big: large extravesicular loop, Intra_loop_2: intravesicular loop 2, Extra_
loop_2: extravesicular loop 2, Intra_loop_3: intravesicular loop 3, Extra_C: carboxy-terminal extra-vesicular portion. All features with ‘membrane’ indicate 
membrane-spanning regions of nsp6. Panel b: Each line represents the encoded nsp6 protein sequence from a single genome, ordered by date of samples 
collection (bottom earliest, top most recent). Coloured markers indicate the positions of amino acid (aa) substitutions from the reference strain sequence, 
only substitutions observed in multiple genomes are annotated with the annotation (original aa position new aa) and the labels were placed as close as 
possible to the substitution.














Extended Data Fig. 3 | Changes in A.23/A.23.1 ORF8 protein. The encoded ORF8 protein from all Ugandan A.23 and A.23.1 genomes gather, aligned 
and compared to the ORF8 protein from GenBank NC_045512.2. Panel a: The locations of important ORF8 protein features are indicated based on the 
analysis of ORF8 from Flower et al.5. Features with ‘Beta’ indicate beta-sheets, ORF8_specific is a region unique to SARS-CoV-2 ORF8, CLP_turn: indicates 
a cysteine, Leucine, Proline motif essential for a fold in the mature protein, Dimer interface2 indicates the region of the protein the forms the interface 
between two monomers. Panel b: Each line represents the encoded ORF8 protein sequence from a single genome, ordered by date of samples collection 
(bottom earliest, top most recent). Coloured markers indicate the positions of amino acid (aa) substitutions from the reference strain sequence, only 
substitutions observed in multiple genomes are annotated with the annotation (original aa position new aa) and the labels were placed as close as 
possible to the substitution.
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Extended Data Fig. 4 | Changes in A.23/A.23.1 ORF9 protein. The encoded ORF9 protein from all Ugandan A.23 and A.23.1 genomes gather, aligned 
and compared to the ORF9 protein from GenBank NC_045512.2. Panel a: The locations of important ORF9 protein features are indicated based on the 
analysis of ORF9 from Chang et al.6. N-term: amino-terminal extension, NTD: amino-terminal domain, linker: linker region between the NTD and CTD, 
CTD: carboxy-terminal domain, C-tail: carboxy-terminal extension, Regions with ‘Basic’ indicate the 4 regions enriched in positively charged amino acids. 
Panel b: Each line represents the encoded ORF9 protein sequence from a single genome, ordered by date of samples collection (bottom earliest, top 
most recent). Coloured markers indicate the positions of amino acid (aa) substitutions from the reference strain sequence, only substitutions observed in 
multiple genomes are annotated with the annotation (original aa position new aa) and the labels were placed as close as possible to the substitution.
NATURE MICROBIOLOgy | www.nature.com/naturemicrobiology
Articles NATURE MICRObIOLOgy
Extended Data Fig. 5 | a, Percentage of total cases reported at the end of January 2021 were plotted by district (Perc_cases, dark blue bars). Only districts 
reporting 10 or more cases in the period were included. For the same districts, the percentage of total genomes obtained were plotted (Perc_genomes, 
light blue bars). The source data for Extended Data Fig. 5a can be found in Supplementary Table 2. b, District location of cases yielding full genome 
sequences. The district location in Uganda of cases from which full genome sequences are plotted on a map of Uganda. Districts with >10 genomes were 
marked in red, 2-10 genomes marked in blue and 1 genome marked in grey. Land masses are indicated in light grey, and lakes are indicate in pale blue.
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